Determination of SK&F 108566 (Teveten) in human plasma by reversed-phase high-performance liquid chromatography.
A sensitive, selective and rugged analytical method was developed for the determination of SK&F 108566 (eprosartan, Teveten) in human plasma. The new method employs a simple solid-phase extraction procedure to isolate the drug and its internal standard (SB-200062) from plasma samples. The assay is based on analysis by reversed-phase high-performance liquid chromatography with ultraviolet absorbance detection. The dynamic range of the assay is from 10.0 to 5000 ng/ml, based on 0.5-ml aliquots of plasma. No interference from the endogenous components of plasma, the anticoagulant, or sample collection devices have been noted. The assay has been fully validated. The mean within-run precision (6.5%), between-run precision (4.0%), accuracy (106%) and recovery (71.8%) of the method were considered acceptable. Additionally, SK&F 108566 was found to be stable in plasma under the storage and sample preparation conditions used. This assay has been successfully employed to provide pharmacokinetic data from clinical trials.
Lundberg
D E
DE
Department of Drug Metabolism and Pharmacokinetics, SmithKline Beecham Pharmaceuticals, King of Prussia, PA 19406-0939, USA.
Person
C R
CR
Knox
S
S
Cyronak
M J
MJ
D000179:Acrylates / Q000097:blood* / Q000493:pharmacokinetics; D000804:Angiotensin II / Q000037:antagonists & inhibitors*; D002138:Calibration; D002851:Chromatography, High Pressure Liquid; D006801:Humans; D007093:Imidazoles / Q000097:blood* / Q000493:pharmacokinetics; D007202:Indicators and Reagents; D011786:Quality Control; D012015:Reference Standards; D015203:Reproducibility of Results; D013056:Spectrophotometry, Ultraviolet; D013876:Thiophenes
D000179:Acrylates; D007093:Imidazoles; D007202:Indicators and Reagents; D013876:Thiophenes; D000804:Angiotensin II; C068373:eprosartan